These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11730847)

  • 1. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA.
    Liabakk NB; Sundan A; Torp S; Aukrust P; Frøland SS; Espevik T
    J Immunol Methods; 2002 Jan; 259(1-2):119-28. PubMed ID: 11730847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
    Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
    Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease.
    Rus V; Zernetkina V; Puliaev R; Cudrici C; Mathai S; Via CS
    Clin Immunol; 2005 Oct; 117(1):48-56. PubMed ID: 15961346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of monoclonal antibodies directed against trail or trail receptors.
    Vermot-Desroches C; Sergent E; Bonnin B; Wijdenes J
    Cell Immunol; 2005; 236(1-2):86-91. PubMed ID: 16157319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.
    Tecchio C; Huber V; Scapini P; Calzetti F; Margotto D; Todeschini G; Pilla L; Martinelli G; Pizzolo G; Rivoltini L; Cassatella MA
    Blood; 2004 May; 103(10):3837-44. PubMed ID: 14726404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
    Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
    J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies against TRAIL.
    Liabakk NB; Espevik T
    Vitam Horm; 2004; 67():65-79. PubMed ID: 15110172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.
    Bremer E; Kuijlen J; Samplonius D; Walczak H; de Leij L; Helfrich W
    Int J Cancer; 2004 Mar; 109(2):281-90. PubMed ID: 14750182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
    Casari G; Dall'Ora M; Melandri A; Masciale V; Chiavelli C; Prapa M; Neri G; Spano MC; Murgia A; D'Esposito A; Baschieri MC; Ceccherelli GB; Dominici M; Grisendi G
    Cytotherapy; 2023 Jun; 25(6):605-614. PubMed ID: 37012089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interleukin-12 enhanced tumor necrosis factor related apoptosis-inducing ligand TRAIL-induced apoptosis in human hepatocellular carcinoma by inhibiting expression of survivin].
    He SQ; Chen Y; Chen XP; Zhang WG; Wang HP; Zhang BX
    Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):453-7. PubMed ID: 12895357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic changes of apoptosis-inducing ligands and Th1/Th2 like subpopulations in Hantaan virus-induced hemorrhagic fever with renal syndrome.
    Liu JM; Zhu Y; Xu ZW; Ouyang WM; Wang JP; Liu XS; Cao YX; Li Q; Fang L; Zhuang R; Yang AG; Jin BQ
    Clin Immunol; 2006 Jun; 119(3):245-51. PubMed ID: 16616877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
    Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
    J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
    Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
    Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
    Tanaka H; Ito T; Kyo T; Kimura A
    Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The release of soluble forms of TRAIL and DR5 by neutrophils of oral cavity cancer patients.
    Jablonska E; Jablonski J; Marcinczyk M; Grabowska Z; Piotrowski L
    Folia Histochem Cytobiol; 2008; 46(2):177-83. PubMed ID: 18519235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes.
    Campioni D; Secchiero P; Corallini F; Melloni E; Capitani S; Lanza F; Zauli G
    Am J Pathol; 2005 Feb; 166(2):557-63. PubMed ID: 15681838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation.
    Nomura S; Ishii K; Inami N; Uoshima N; Ishida H; Yoshihara T; Kitayama H; Hayashi K
    Transpl Immunol; 2007 Nov; 18(2):115-21. PubMed ID: 18005854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival.
    Pritzker LB; Scatena M; Giachelli CM
    Mol Biol Cell; 2004 Jun; 15(6):2834-41. PubMed ID: 15064358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
    Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
    Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
    Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
    Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.